Lunai Bioworks (LNAI) Common Equity (2011 - 2026)

Lunai Bioworks' Common Equity history runs 16 years deep, the most recent figure standing at -$9.6 million for Q1 2026.

• In Q1 2026, Common Equity fell 110.81% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at -$9.6 million (down 110.81% YoY), while the FY2025 annual figure was -$21.3 million, down 116.18% from the prior year.
• Common Equity was -$9.6 million for Q1 2026 at Lunai Bioworks, up from -$13.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $161.2 million in Q1 2022 to a low of -$21.3 million in Q2 2025.
• Historically, Common Equity has averaged $61.9 million across 5 years, with a median of $66.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity soared 183.81% in 2024, then tumbled 116.51% in 2025.
• A 5-year view of Common Equity shows it stood at $66.9 million in 2022, then sank by 34.83% to $43.6 million in 2023, then surged by 88.23% to $82.1 million in 2024, then sank by 116.51% to -$13.5 million in 2025, then climbed by 29.49% to -$9.6 million in 2026.
• The last three Common Equity figures came in at -$9.6 million (Q1 2026), -$13.5 million (Q4 2025), and -$13.0 million (Q3 2025), per Business Quant data.